Numinus Wellness Inc. Announces Third Quarter Fiscal 2024 Results Jul 11, 2024 04:30PM
Numinus to Host Q3 Fiscal 2024 Results Conference Call on July 11, 2024 Jul 10, 2024 06:35PM
Numinus Wellness Announces Resignation of Director Jun 24, 2024 05:30PM
Numinus Wellness Announces Voting Results From its Annual General Meeting of Shareholders May 31, 2024 07:38PM
Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy May 30, 2024 07:00AM
View Older Stories

Apr 15, 2024 07:41AM Numinus Wellness Provides Corporate Update
Apr 12, 2024 07:49PM Numinus Wellness Inc. Announces Second Quarter Fiscal 2024 Results
Apr 9, 2024 07:00AM Numinus to Host Q2 Fiscal 2024 Results Conference Call on April 15, 2024
Mar 20, 2024 07:00AM Numinus Wellness Submits Clinical Trial Application
Mar 12, 2024 07:00AM Numinus Wellness Provides Corporate Update
Mar 8, 2024 07:00AM Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
Feb 1, 2024 07:00AM Numinus Wellness Divests of Holdings in Alto Neuroscience Inc.
Feb 1, 2024 07:00AM /C O R R E C T I O N from Source -- Numinus Wellness Inc./
Jan 15, 2024 05:00PM Numinus Wellness Inc. Announces First Quarter Fiscal 2024 Results
Jan 2, 2024 05:00PM Numinus to Host Q1 Fiscal 2024 Results Conference Call on January 15, 2024
Dec 15, 2023 10:26AM Cedar Clinical Research selected as clinical research site for Beckley Psytech's Phase 2b Study
Dec 13, 2023 07:00AM Numinus Congratulates MAPS on its Application to the FDA for MDMA-Assisted Therapy for PTSD
Nov 29, 2023 05:00PM Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results
Nov 21, 2023 08:00AM Numinus to Host Q4 2023 and Annual Results Conference Call on November 29, 2023
Oct 3, 2023 07:00AM Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research
Sep 25, 2023 07:16PM Numinus Wellness Inc. Announces At-The-Market Offering Equity Program
Sep 19, 2023 07:00AM Numinus Congratulates MAPS on its Phase 3 Study Results Published in Nature Medicine
Sep 18, 2023 06:45PM Numinus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations
Aug 9, 2023 07:00AM Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023
Jul 17, 2023 04:01PM Numinus Wellness Inc. Reports Q3 2023 Results
Jul 10, 2023 06:29PM Numinus to Present at the Small Cap Growth Virtual Investor Conference on July 13, 2023
Jun 29, 2023 07:00AM Numinus to Host Q3 2023 Results Conference Call on July 17, 2023
Jun 22, 2023 07:00AM Numinus Announces Agreement with HealingMaps to Drive Strategic Clinic Growth
Jun 15, 2023 07:00AM Numinus Announces Partnership with MAPS to Support Therapist Psychedelic Experiential Training
Jun 14, 2023 07:00AM Numinus Appoints New Chief Financial Officer
Jun 8, 2023 07:00AM Numinus to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023
Jun 5, 2023 07:00AM Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120
Jun 2, 2023 07:00AM Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023
May 30, 2023 07:00AM Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study
May 25, 2023 07:00AM Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy
Apr 17, 2023 07:00AM Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, April 19, 2023
Apr 14, 2023 07:00AM Numinus Launches New Website to Enhance its Client Experience
Apr 13, 2023 04:01PM Numinus Wellness Inc. Reports Q2 2023 Results
Apr 11, 2023 07:00AM Numinus Launches new Clinic Licensing Platform, the Numinus Network, to Accelerate Expansion
Mar 30, 2023 07:00AM Numinus to Host Q2 2023 Results Conference Call on April 13, 2023
Mar 27, 2023 07:00AM Numinus Launches the Practitioner Certification Pathway - a Complete Psychedelic-Assisted Therapy Training Program
Mar 22, 2023 07:00AM Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
Mar 21, 2023 07:00AM Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023
Mar 7, 2023 07:00AM Numinus Wellness Inc. Executives to Present on Panel at Upcoming South by Southwest Conference
Feb 24, 2023 07:00AM Numinus to Participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023
Feb 17, 2023 07:00AM Numinus Expands Research Capabilities with new Phoenix Clinical Research Site
Feb 15, 2023 05:00PM Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders
Feb 1, 2023 07:00AM Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea
Jan 16, 2023 04:01PM Numinus Wellness Inc. Reports Q1 2023 Results
Jan 4, 2023 07:00AM Numinus to Host Q1 2023 Results Conference Call on January 16, 2023
Dec 12, 2022 04:10PM Numinus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022
Dec 8, 2022 07:00AM Numinus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research
Nov 29, 2022 04:15PM Numinus Wellness Inc. Reports Q4 2022 and Annual Results
Nov 22, 2022 07:00AM Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022
Nov 15, 2022 07:00AM Numinus to Host Q4 and Year End 2022 Results Conference Call on November 29, 2022
View Older Stories